Maintenance therapies in bipolar disorders

Bipolar Disorders

Volumn 14, Issue SUPPL.2, 2012, Pages 51-65

  Gitlin, Michael ^a   Frye, Mark A ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Anticonvulsants; Antipsychotics; Bipolar disorder; Lithium; Maintenance; Treatment

Indexed keywords

ANTICONVULSIVE AGENT; ARIPIPRAZOLE; CARBAMAZEPINE; LAMOTRIGINE; LITHIUM; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; OXCARBAZEPINE; QUETIAPINE; RISPERIDONE; VALPROIC ACID; ZIPRASIDONE;

AGRANULOCYTOSIS; AKATHISIA; APLASTIC ANEMIA; ATAXIA; BIPOLAR DISORDER; BLURRED VISION; CONCENTRATION LOSS; DEPRESSION; DIABETES MELLITUS; DIARRHEA; DIPLOPIA; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; EXTRAPYRAMIDAL SYMPTOM; HAIR LOSS; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPONATREMIA; INSOMNIA; MAINTENANCE THERAPY; MANIA; MEMORY DISORDER; METABOLIC SYNDROME X; MIXED MANIA AND DEPRESSION; MONOTHERAPY; MOOD CHANGE; MORBIDITY; NAUSEA; PATIENT COMPLIANCE; POLYDIPSIA; POLYURIA; PRIORITY JOURNAL; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; REVIEW; SEDATION; SIDE EFFECT; SUICIDE; SYSTEMATIC REVIEW; TREATMENT DURATION; TREMOR; VOMITING; WEIGHT GAIN;

ANTICONVULSANTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84859851346     PISSN: 13985647     EISSN: 13995618     Source Type: Journal    
DOI: 10.1111/j.1399-5618.2012.00992.x     Document Type: Review

References (96)

1. Goodwin FK, Jamison KR. Course and outcome. In: Manic-Depressive Illness-Bipolar Disorders and Recurrent Depression. New York: Oxford University Press, Inc., 2007: 119-154.
2. Gitlin MJ, Swendsen J, Heller TL, Hammen C. Relapse and impairment in bipolar disorder. Am J Psychiatry 1995; 152: 1635-1640.
3. Perlis RH, Ostacher MJ, Patel JK et al. Predictors of recurrence in bipolar disorder: primary outcomes from the systematic treatment enhancement program for bipolar disorder (STEP-BD). Am J Psychiatry 2006; 163: 217-224.
4. Keller MB, Lavori PW, Coryell W, Endicott J, Mueller TI. Bipolar I: a five-year prospective follow-up. J Nerv Ment Dis 1993; 181: 238-245.
5. Judd LL, Akiskal HS, Schetteler PJ et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002; 59: 530-537.
6. Baldessarini RJ, Salvatore P, Khalsa H-MK et al. Morbidity in 303 first-episode bipolar I disorder patients. Bipolar Disord 2010; 12: 264-270.
7. Judd LL, Akiskal HS, Schettler PJ et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry 2003; 60: 261-269.
8. Simon GE, Bauer MS, Ludman EJ, Operskalski BH, Unützer J. Mood symptoms, functional impairment, and disability in people with bipolar disorder: specific effects of mania and depression. J Clin Psychiatry 2007; 68: 1237-1245.
9. Tohen M, Frank E, Bowden CL et al. The International Society for Bipolar Disorders (ISBD) Task Force report on the nomenclature of course and outcome in bipolar disorders. Bipolar Disord 2009; 11: 453-473.
10. Gitlin MJ, Abulseoud O, Frye MA. Improving the design of maintenance studies for bipolar disorder. Curr Med Res Opin 2010; 26: 1835-1842.
11. Judd LL, Schettler PJ, Akiskal HS et al. Residual symptom recovery from major affective episodes in bipolar disorders and rapid episode relapse/recurrence. Arch Gen Psychiatry 2008; 65: 386-394.
12. Frye MA, Yatham LN, Calabrese JR et al. Incidence and time course of subsyndromal symptoms in patients with bipolar I disorder: an evaluation of 2 placebo-controlled maintenance trials. J Clin Psychiatry 2006; 67: 1721-1728.
13. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002; 159: 1-50.
14. Yatham LN, Kennedy SH, Schaffer A et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord 2009; 11: 225-255.
15. Malhi GS, Adams D, Lampe L et al.. Clinical practice recommendations for bipolar disorder. Acta Psychiatr Scand 2009: 119 (Suppl. 439): 27-46.
16. Goodwin GM. Consensus Group of the British Association for Psychopharmacology. Evidence-based guidelines for treating bipolar disorder: revised second edition - recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2009; 23: 346-388.
17. Goodwin FK, Jamison KR. Medication adherence. In: Manic-Depressive Illness-Bipolar Disorders and Recurrent Depression. New York: Oxford University Press, Inc., 2007: 849-868.
18. Frye A, Ketter TA, Leverich GS et al. The increasing use of polypharmacotherapy for refractory mood disorders: 22years of study. J Clin Psychiatry 2000; 61: 9-15.
19. Levine J, Chengappa KNR, Brar JS et al. Psychotropic drug prescription patterns among patients with bipolar I disorder. Bipolar Disord 2000; 2: 120-130.
20. Nolen WA, Luckenbaugh DA, Altshuler LL et al. Correlates of 1-year prospective outcome in bipolar disorder: results from the Stanley foundation bipolar network. Am J Psychiatry 2004; 161: 1447-1454.
21. Goldberg JF, Brooks JO, Kurita K et al. Depressive illness burden associated with complex polypharmacy in patients with bipolar disorder: findings from the STEP-BD. J Clin Psychiatry 2009; 70: 155-162.
22. Goodwin FK, Jamison KR. Maintenance medical treatment. In: Manic-Depressive Illness-Bipolar Disorders and Recurrent Depression. New York: Oxford University Press, Inc., 2007: 797-848.
23. Tohen M, Calabrese JR, Sachs GS et al. Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. Am J Psychiatry 2006; 163: 247-256.
24. Baastrup PC, Mogens S. Lithium as a prophylactic agent: its effect against recurrent depressions and manic-depressive psychosis. Arch Gen Psychiatry 1967; 16: 162-172.
25. Prien RF, Point P, Caffey EM, Klett CJ. Prophylactic efficacy of lithium carbonate in manic-depressive illness. Arch Gen Psychiatry 1973; 28: 337-341.
26. Suppes T, Baldessarini RJ, Faedda GL, Tohen M. Risk of recurrence following discontinuation of lithium treatment in bipolar disorder. Arch Gen Psychiatry 1991; 48: 1082-1088.
27. Baldessarini RJ, Tondo L, Faedda GL, Suppes TR, Floris G, Rudas N. Effects of the rate of discontinuing lithium maintenance treatment in bipolar disorders. J Clin Psychiatry 1996; 57: 441-448.
28. Baldessarini RJ, Tondo L, Floris G, Rudas N. Reduced morbidity after gradual discontinuation of lithium treatment for bipolar I and II disorders: a replication study. Am J Psychiatry 1997; 154: 551-553.
29. Baldessarini RJ, Tondo L, Viguera AC. Discontinuing lithium maintenance treatment in bipolar disorders: risks and implications. Bipolar Disord 1999; 1: 17-24.
30. Malhi GS, Adams D, Berk M. Is lithium in a class of its own? A brief profile of its clinical use. Aust N Z J Psychiatry 2009; 43: 1096-1104.
31. Gershon S, Chengappa KNR, Malhi GS. Lithium specificity in bipolar illness: a classic agent for the classic disorder. Bipolar Disord 2009; 11 (Suppl. 2): 34-44.
32. Bowden CL, Calabrese JR, McElroy SL et al. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Arch Gen Psychiatry 2000; 57: 481-489.
33. Bowden CL, Calabrese JR, Sachs G et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry 2003; 60: 392-400.
34. Calabrese JR, Bowden CL, Sachs G et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry 2003; 64: 1013-1024.
35. Weisler RH, Nolen WA, Neijber A et al. Continuation of quetiapine versus switching to placebo or lithium for maintenance treatment of bipolar I disorder (Trial 144: A randomized controlled study). J Clin Psychiatry 2011; 72: 1452-1464.
36. Geddes JR, Burgess S, Hawton K, Jamison K, Goodwin GM. Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials. Am J Psychiatry 2004; 161: 217-222.
37. Smith LA, Cornelius V, Warnock A, Bell A, Young AH. Effectiveness of mood stabilizers and antipsychotics in the maintenance phase of bipolar disorder: a systematic review of randomized controlled trials. Bipolar Disord 2007; 9: 394-412.
38. Popovic D, Reinares M, Amann B, Salamero M, Vieta E. Number needed to treat analyses of drugs used for maintenance treatment of bipolar disorder. J Psychopharmacol 2011; 213: 657-667.
39. Kleindienst N, Engel RR, Greil W. Which clinical factors predict response to prophylactic lithium? A systematic review for bipolar disorders. Bipolar Disord 2005; 7: 404-417.
40. Pfennig A, Schlattmann P, Alda M, et al. Influence of atypical features on the quality of prophylactic effectiveness of long-term lithium treatment in bipolar disorders. Bipolar Disord 2010; 12: 390-396.
41. Calabrese JR, Shelton MD, Rapport DJ et al. A 20-month, double-blind, maintenance trial of lithium versus divalproex in rapid-cycling bipolar disorder. Am J Psychiatry 2005; 162: 2152-2161.
42. Macritchie KA, Geddes JR, Scott J, Haslam DR, Goodwin GM. Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder (Review). Cochrane Database Syst Rev 2001; 3: 1-23.
43. Gyulai L, Bowden CL, McElroy SL et al. Maintenance efficacy of divalproex in the prevention of bipolar depression. Neuropsychopharmacology 2003; 28: 1374-1382.
44. BALANCE investigators and collaborators, Geddes JR, Goodwin GM et al.. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomized open-label trial. Lancet 2010; 375: 385-395.
45. Bowden CL, Brugger AM, Swann AC et al. Efficacy of divalproex vs lithium and placebo in the treatment of mania. JAMA 1994; 271: 918-924.
46. Bowden CL, Swann AC, Calabrese JR et al. A randomized, placebo-controlled, multicenter study of divalproex sodium extended release in the treatment of acute mania. J Clin Psychiatry 2006; 67: 1501-1510.
47. Goodwin GM, Bowden CL, Calabrese JR, et al. A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. J Clin Psychiatry 2004; 65: 432-439.
48. Licht RW, Nielsen JN, Gram LF, Vestergaard P, Bendz H. Lamotrigine versus lithium as maintenance treatment in bipolar I disorder: an open, randomized effectiveness study mimicking clinical practice. The 6th trial of the Danish University Antidepressant Group (DUAG-6). Bipolar Disord 2010; 12: 483-493.
49. van der Loos MLM, Mulder P, Hartong EGThM et al. Long-term outcome of bipolar depressed patients receiving lamotrigine as add-on to lithium with the possibility of the addition of paroxetine in nonresponders: a randomized, placebo-controlled trial with a novel design. Bipolar Disord 2011; 13: 111-117.
50. Calabrese JR, Suppes T, Bowden CL et al. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. J Clin Psychiatry 2000; 61: 841-850.
51. Okuma T, Inanaga K, Otsuki S, et al. A preliminary double-blind study on the efficacy of carbamazapine in prophylaxis of manic-depressive illness. Psychopharmacol 1981; 73: 95-96.
52. Greil W, Ludwig-Mayerhofer W, Erazo N et al. Lithium versus carbamazepine in the maintenance treatment of bipolar disorders - a randomized study. J Affect Disord 1997; 43: 151-161.
53. Hartong EGThM, Moleman P, Hoogduin CAL, Broekman TG, Nolen WA, LitCar Group. Prophylactic efficacy of lithium versus carbamazepine in treatment-naive bipolar patients. J Clin Psychiatry 2003; 64: 144-151.
54. Kleindienst N, Greil W. Differential efficacy of lithium and carbamazepine in the prophylaxis of bipolar disorder: results of the MAP study. Neuropsychobiology 2000; 42 (Suppl.1): 2-10.
55. Denicoff KD, Smith-Jackson EE, Disney ER, Ali SO, Leverich GS, Post RM. Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder. J Clin Psychiatry 1997; 58: 470-478.
56. Vieta E, Cruz N, Garcia-Campayo J et al. A double-blind, randomized, placebo-controlled prophylaxis trial of oxcarbazepine as adjunctive treatment to lithium in the long-term treatment of bipolar I and II disorder. Int J Neuropsychopharmacol 2008; 11: 445-452.
57. Mishory A, Winokur M, Bersudsky Y. Prophylactic effect of phenytoin in bipolar disorder: a controlled study. Bipolar Disord 2003; 5: 464-467.
58. Vieta E, Torrent C, Garcia-Ribas G et al. Use of topiramate in treatment-resistant bipolar spectrum disorders. J Clin Psychopharm 2002; 22: 431-435.
59. McIntyre RS, Riccardelli R, Binder C, Kusumakar V. Open-label adjunctive topiramate in the treatment of unstable bipolar disorder. Can J Psychiatry 2005; 50: 415-422.
60. Tohen M, Chengappa KNR, Suppes T et al. Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabilizer v. mood stabilizer alone. Br J Psychiatry 2004; 184: 337-345.
61. Tohen M, Greil W, Calabrese JR et al. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial. Am J Psychiatry 2005; 162: 1281-1290.
62. Keck PE Jr, Calabrese JR, McQuade RD et al. A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. J Clin Psychiatry 2006; 64: 626-637.
63. Keck PE Jr, Calabrese JR, McIntyre RS et al. Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: A 100-week, double-blind study versus placebo. J Clin Psychiatry 2007; 68: 1480-1491.
64. Marcus R, Khan A, Rollin L et al. Efficacy of aripiprazole adjunctive to lithium or valproate in the long-term treatment of patients with bipolar I disorder with an inadequate response to lithium or valproate monotherapy: a multicenter, double-blind, randomized study. Bipolar Disord 2011; 13: 133-144.
65. Vieta E, Suppes T, Eggens I, Persson I, Paulsson B, Brecher M. Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126). J Affect Disord 2008; 109: 251-263.
66. Suppes T, Vieta E, Liu S, Brecher M, Paulsson B. Trial 127 Investigators. Maintenance treatment for patients with bipolar I disorder: results from a north american study of quetiapine in combination with lithium or divalproex. Am J Psychiatry 2009; 166: 476-488.
67. Bowden CL, Vieta E, Ice KS, Schwartz JH, Wang PP, Versavel M. Ziprasidone plus a mood stablilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial. J Clin Psychiatry 2010; 71: 130-137.
68. Macfadden W, Alphs L, Haskins JT et al. A randomized, double-blind, placebo-controlled study of maintenance treatment with adjunctive risperidone long-acting therapy in patients with bipolar I disorder who relapse frequently. Bipolar Disord 2009; 11: 827-839.
69. Quiroz JA, Yatham LN, Palumbo JM, Karcher K, Kushner S, Kusumakar V. Risperidone long-acting injectable monotherapy in the maintenance treatment of bipolar I disorder. Biol Psychiatry 2010; 68: 156-162.
70. Frye MA, Ketter TA, Altshuler LL, Denicoff K et al. Clozapine in bipolar disorder: treatment implications for other atypical antipsychotics. J Affect Disord 1998; 48: 91-104.
71. Suppes T, Webb A, Paul B, Carmody T, Kraemer H, Rush AJ. Clinical outcome in a randomized 1-year trial of clozapine versus treatment as usual for patients with treatment-resistant illness and a history of mania. Am J Psychiatry 1999; 156: 1164-1169.
72. Gitlin MJ, Cochran SD, Jamison KR. Maintenance lithium treatment: side effects and compliance. J Clin Psychiatry 1989; 50: 127-131.
73. Vestergaard P, Amdisen A, Schou M. Clinically significant side effects of lithium treatment a survey of 237 patients in long-term treatment. Acta Psychiatr Scand 1980; 62: 193-200.
74. Gitlin M. Lithium and the kidney: an updated review. Drug Safety 1999; 20: 231-243.
75. Jefferson JW. Lithium: a therapeutic magic wand. J Clin Psychiatry 1989; 50: 81-86.
76. Bendz H, Schön S, Attman PO, Aurell M. Renal failure occurs in chronic lithium treatment but is uncommon. Kidney Int 2010; 77: 219-224.
77. Kleiner J, Altshuler L, Hendrick V, Hershman JM. Lithium-induced subclinical hypothyroidism: review of the literature and guidelines for treatment. J Clin Psychiatry 1999; 60: 249-255.
78. Frye MA, Denicoff KD, Bryan AL, Smith-Jackson E, Post RM. Association between lower serum free T4 and greater mood instability and depression in lithium-maintained bipolar patients. Am J Psychiatry 1999; 156: 1909-1914.
79. Frye MA, Yatham L, Ketter TA et al. Depressive relapse during lithium treatment associated with increased serum thyroid-stimulating hormone: results from two placebo-controlled bipolar I maintenance studies. Acta Psychiatr Scand 2009; 120: 10-13.
80. Dreifuss FE, Langer DH. Side effects of valproate. Am J Med 1988; 84: 34-41.
81. Rasgon NL, Altshuler LL, Fairbanks L et al. Reproductive function and risk for PCOS in women treated for bipolar disorder. Bipolar Disord 2005; 7: 246-259.
82. Joffe H, Cohen LS, Suppes T et al. Valproate is associated with new-onset oligoamenorrhea with hyperandrogenism in women with bipolar disorder. Biol Psychiatry 2006; 59: 1078-1086.
83. Koren G, Nava-Ocampo AA, Moretti ME, Sussman R, Nulman I. Major malformations with valproic acid. Can Fam Physician 2006; 52: 441-447.
84. Seo HJ, Chiesa A, Lee SJ et al. Safety and tolerability of Lamotrigine: results from 12 placebo-controlled clinical trials and clinical implications. Clin Neuropharmacol 2011; 34: 39-47.
85. Mockenhaupt M, Messenheimer J, Tennis P, Schlingmann J. Risk of stevens-johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics. Neurology 2005; 64: 1134-1138.
86. Mazza M, Di Nicola M, Martinotti G et al. Oxcarbazepine in bipolar disorder: a critical review of the literature. Expert Opin Pharmacother 2007; 8: 649-656.
87. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 2004; 161: 414-425.
88. Houseknecht KL, Robertson AS, Zavadoski W, Gibbs EM, Johnson DE, Rollema H. Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects. Neuropsychopharmacol 2007; 32: 289-297.
89. Henderson DC, Cagliero E, Copeland PM et al. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch Gen Psychiatry 2005; 62: 19-28.
90. Henderson DC, Cagliero E, Gray C et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am J Psychiatry 2000; 157: 975-981.
91. Vieta E, Owen R, Baudelet C, McQuade RD, Sanchez R, Marcus RN. Assessment of safety, tolerability and effectiveness of adjunctive aripiprazole to lithium/valproate in bipolar mania: a 46-week, open-label extension following a 6-week double-blind study. Curr Med Res Opin 2010; 26: 1485-1496.
92. Brecher M, Leong RW, Stening G, Osterling-Koskinen L, Jones M. Quetiapine and long-term weight change: a comprehensive data review of patients with schizophrenia. J Clin Psychiatry 2007; 68: 597-603.
93. Koller EA, Weber J, Doraiswamy PM, Schneider BS. A survey of reports of quetiapine-associated hyperglycemia and diabetes mellitus. J Clin Psychiatry 2004; 65: 857-863.
94. Taylor D. Ziprasidone in the management of schizophrenia: the QT interval issue in context. CNS Drugs 2003; 17: 423-430.
95. Beynon S, Soares-Weiser K, Woolacott N, Duffy S, Geddes JR. Psychosocial interventions for the prevention of relapse in bipolar disorder: systematic review of controlled trials. Br J Psychiatry 2008; 192: 5-11.
96. Miklowitz DJ. Adjunctive psychotherapy for bipolar disorder: state of the evidence. Am J Psychiatry 2008; 165: 1408-1419.